# Counter-Analysis: MMC (Marsh McLennan)

## Fecha: 2026-02-13

## Resumen Ejecutivo

The MMC thesis describes an exceptional business -- and on this point, the thesis is largely correct. MMC is the undisputed #1 global insurance broker with a WIDE moat. However, the R1 analyses contain several material gaps and optimistic assumptions that, if unresolved, could lead to capital deployed at insufficient margin of safety. The most significant issues are: (1) the thesis FV of $220 was correctly revised to $190 by the valuation-specialist, but the thesis header still shows $220 creating a 14% discrepancy that must be resolved; (2) the Greensill Australia mega-trial (A$7B+, starting August 2026) is a genuine tail risk that could absorb $500M-$1B+ of cash flow and was insufficiently quantified; (3) the organic growth deceleration from 7% to 4% may not be purely cyclical -- it coincides with structural P&C rate softening that could persist 2-3 years; (4) the thesis dismisses the AI disruption narrative too easily, particularly for the ~35% consulting segment (Mercer + Oliver Wyman) which faces more direct AI risk than the broking segment. The thesis survives scrutiny as a sound business analysis but requires FV calibration and a hard gate on the Greensill trial before any capital deployment.

---

## Asunciones Clave Desafiadas

### 1. Assumption: Organic growth deceleration is cyclical (4% is a trough, will revert to 6-7%)

- **Evidencia en contra:** FY2025 organic growth was 4% across ALL four quarters (Q1-Q4), not an isolated quarter. This is not a V-shaped trough but a sustained deceleration. Management guided FY2026 "similar to 2025," explicitly confirming 4% organic growth as the new baseline. BofA downgraded to Underperform citing "no near-term catalysts for organic growth recovery." Property cat reinsurance rates fell 14.7% in Jan 2026 renewals (largest decline since 2014) and Guy Carpenter flagged this as a 2026 headwind. Fiduciary interest income declined $20M YoY in Q4 2025 alone, with further declines expected. RBC, Mizuho, and consensus all project 4% organic growth in 2026 and only 5% in 2027 -- not the 6-7% the thesis implicitly assumes for its bull case.
- **What the thesis says:** "4% organic growth in an insurance market transitioning from hard to soft is actually RESILIENT." This framing is correct -- but being resilient at 4% is different from reverting to 7%.
- **Severidad:** MODERATE -- The thesis already prices in 4% organic, and entry at $160 provides buffer. But the assumption that organic growth reverts to 6%+ drives the bull case and inflates expected value.
- **Resolucion sugerida:** Cap base case organic growth at 4% for 2026-2027, with 5% from 2028 only if hard market returns. This would reduce the DCF-derived FV.

### 2. Assumption: Greensill litigation is "bounded" and manageable

- **Evidencia en contra:** The A$7B+ Australian Greensill Proceedings are NOT legacy. A five-month trial starts August 2026. An Australian Federal Court ruled AGAINST Marsh in October 2025 on procedural matters (anti-anti-suit injunction), demonstrating the court is unfavorable to Marsh's defense strategy. Marsh has been named defendant in 7 of 11 proceedings. The thesis estimates Marsh's share at $450M-$900M but provides no basis for this estimate. The full A$7B relates to claims where Marsh allegedly misrepresented insurance coverage -- if the court finds FRAUD (not just negligence), the exposure escalates dramatically: (a) punitive damages could apply, (b) E&O insurance may NOT cover fraudulent acts, and (c) reputational damage for a broker whose entire value proposition is trust would be severe. The UK White Oak settlement ($143M) was resolved quickly, but the Australian proceedings are orders of magnitude larger and the court has been hostile.
- **What the thesis says:** "FCF of $5B/year provides capacity to absorb a material settlement."
- **What the risk assessment says:** Correctly identifies this as HIGH risk with potential $500M-$1B impact but does NOT recommend it as a hard gate.
- **Severidad:** HIGH -- This is a genuine binary risk event with uncertain but potentially large payoff. The trial starting 6 months from now means any position taken now faces this event without resolution.
- **Resolucion sugerida:** The Greensill trial (August 2026) should be treated as a HARD GATE similar to earnings events. Entry at $160 should be conditional on either (a) pre-trial settlement or (b) position sizing that can absorb a $1B adverse outcome without triggering a kill condition.

### 3. Assumption: The AI/Insurify disruption is irrelevant to MMC's core business

- **Evidencia en contra:** The thesis correctly notes that Insurify targets personal auto insurance, not complex commercial broking. But the thesis UNDERWEIGHTS two important dimensions:
  - **McGriff is mid-market, not large commercial.** MMC just paid $7.75B for McGriff, which is a mid-market US broker. Mid-market insurance is significantly MORE vulnerable to AI disruption than Fortune 500 complex risk programs. Analysts estimate 16-35% of retail broking earnings at risk from AI. McGriff's $2.5B revenue is disproportionately in standardized commercial products where AI comparison could gain traction within 3-5 years.
  - **Consulting (35% of revenue) faces direct AI risk.** Mercer's HR/benefits consulting and Oliver Wyman's management consulting are NOT protected by the same moat as insurance broking. AI is already disrupting consulting workflows -- routine benefits benchmarking, actuarial calculations, and strategy research can be partially automated. McKinsey, BCG, and Bain are all restructuring for AI. Mercer and OW face the same pressure.
  - **The -31% stock decline is NOT irrational.** BofA, Goldman Sachs, Wells Fargo, and multiple analysts have lowered price targets. The market is not just panic-selling over Insurify -- it is re-pricing the combination of growth deceleration + rate softening + AI disruption + leverage increase. Calling the selloff "overdone" is a narrative, not evidence.
- **What the thesis says:** "AI is an ENABLER for brokers (better analytics, efficiency)" -- this is true for incumbents using AI internally but does not address the EXTERNAL AI disruption of broker intermediation.
- **Severidad:** MODERATE -- AI disruption is a 5-10 year risk for core broking but a 2-5 year risk for McGriff's mid-market segment and the consulting platform. The stock has already de-rated significantly to reflect this.
- **Resolucion sugerida:** Add kill condition: "AI-native broker captures >2% of US mid-market commercial insurance placement within 18 months." Monitor McGriff client retention rates specifically.

### 4. Assumption: Fair value is $220 (thesis) / $190 (valuation-specialist)

- **Evidencia en contra:** There is a CONFLICT between the thesis and the valuation-specialist report. The thesis header says FV $190 (updated post-valuation report), but the body text and scenarios section says FV $220. The valuation-specialist explicitly states: "The thesis FV of $220 is achievable in the BULL scenario ($235) but should not be used as the base case." The valuation-specialist arrived at $190 through three adjustments the thesis did not make: (a) SBC deduction of $394M/year, (b) conservative WACC 8.5% vs 7.5%, (c) blended growth with 40% weight on organic-only scenario. These three adjustments are reasonable and the valuation-specialist's $190 is the more rigorous number. Furthermore, applying our adversarial pattern (9/9 thesis FVs corrected downward avg -16%), a 16% haircut to $190 would yield $160 -- which is exactly the entry price.
- **Independent cross-check:** Goldman Sachs PT $203 (Neutral). BofA PT $181 (Underperform). Wells Fargo PT $199 (Equal Weight). Cantor Fitzgerald PT $208 (Overweight). Consensus median approximately $200. Our $190 is 5% below consensus, which is appropriate for a conservative value investor.
- **The 17x EV/EBIT multiple is the linchpin.** If the market permanently de-rates insurance brokers from 18-20x to 15-16x (reflecting AI risk premium), the base FV drops to $165-175. This is not priced into the valuation.
- **Severidad:** MODERATE -- The valuation-specialist already corrected the thesis FV from $220 to $190 (a 14% haircut). But the thesis document still contains conflicting numbers, and the entry price of $160 provides only 16% MoS vs $190 -- below typical Tier B precedents of 20-25%.
- **Resolucion sugerida:** Adopt $190 as the canonical FV. Consider whether $160 entry provides sufficient MoS given the Greensill tail risk and 4 HIGH risks identified. $150-155 would be more consistent with precedents (21-23% MoS).

### 5. Assumption: McGriff integration will be successful (track record argument)

- **Evidencia en contra:** The "track record" argument is the most common justification for serial acquirer integration success -- but it is also the most common source of complacency. McGriff is $7.75B -- by far MMC's largest acquisition ever. Prior large deals (JLT at ~$5.5B in 2019) were smaller. Specific integration risks:
  - **Talent flight:** Rivals (AJG, Hub, Lockton) are actively recruiting McGriff producers. Insurance broking is a people business -- if key producers leave, they take client relationships with them. The thesis provides no data on retention so far.
  - **Revenue leakage in upper mid-market:** McGriff positioned in the upper middle market may face client conflicts with existing Marsh accounts. Early reports flag this as a risk.
  - **Debt service math is tight:** $7.25B borrowed at ~5% = ~$360M annual interest. McGriff's estimated EBIT contribution is approximately $150-200M in Year 1. The deal is DILUTIVE to earnings for at least 12-18 months before synergies materialize. With organic growth at only 4%, the company needs McGriff to perform to maintain EPS growth trajectory.
  - **Management attention:** The CEO and C-suite are managing a simultaneous rebranding (MMC to Marsh), a massive integration, AI platform buildout (BCS unit), and the Greensill trial -- all in 2026. This is an unusually heavy operational load.
- **Severidad:** MODERATE -- Integration risk is real but bounded. The asset-light model (commissions, not physical assets) makes integration simpler than industrial M&A. FCF of $5B covers the debt service comfortably. But the near-term EPS dilution and talent flight risk are underweighted in the thesis.
- **Resolucion sugerida:** Add monitoring triggers: (a) McGriff revenue retention rate each quarter (>95% required), (b) Net Debt/EBITDA trajectory (must decline below 2.0x by end 2027), (c) named producer departures.

---

## Desafios por Categoria

### Negocio

| # | Desafio | Evidencia | Severidad |
|---|---------|-----------|-----------|
| 1 | Organic growth 4% may be the "new normal" not a cyclical trough | Management guides "similar to 2025" for 2026. Consensus sees 4% in 2026, 5% in 2027. P&C rate softening (-14.7% cat reinsurance) is a multi-year cycle. | MODERATE |
| 2 | Consulting segment (35% revenue) is more AI-vulnerable than thesis acknowledges | Mercer HR benchmarking and Oliver Wyman strategy work face direct AI substitution risk. McKinsey/BCG restructuring for AI is precedent. | MODERATE |
| 3 | McGriff mid-market exposure IS partially addressable by AI | Mid-market commercial insurance (SMB policies) is more standardized than Fortune 500 programs. McGriff's core segment is where AI disruption has the highest probability within 3-5 years. | MODERATE |
| 4 | Moat assessment gives 21/25 but gross margin is BELOW peers | MMC GM 42.3% vs Aon 47.2% and WTW 44.6%. The moat is real but the "highest quality" narrative conflicts with below-peer margins. | LOW |
| 5 | Revenue CAGR of 9.2% is misleading -- includes McGriff inorganic | Organic CAGR is closer to 5-6%. The QS growth score of 16/25 is partially inflated by M&A-driven revenue growth. | LOW |

### Valoracion

| # | Desafio | Evidencia | Severidad |
|---|---------|-----------|-----------|
| 1 | Thesis FV $220 vs valuation-specialist FV $190 = 14% gap | The valuation report explicitly says $220 is bull-case achievable, not base case. Three adjustments (SBC, WACC conservatism, growth blend) account for the gap. | HIGH |
| 2 | Entry $160 provides only 16% MoS vs $190 -- below Tier B precedents | Precedents: ROP $300 = 22% MoS, ACGL $92 = 23% MoS, RACE.MI EUR 270 = 26% MoS. MMC at $160 = 16% MoS is the lowest. | MODERATE |
| 3 | 17x EV/EBIT could be too generous if permanent de-rating occurs | AI disruption fears + rate softening could permanently compress broker multiples from 18-22x to 14-16x. At 15x forward EBIT, FV = $160 (zero margin). | MODERATE |
| 4 | DCF sensitivity is HIGH (130% spread, 62% terminal value) | A 1pp change in WACC moves FV by $30-60/share. This means the "precision" of any FV estimate is +/-15%. | MODERATE |
| 5 | BofA price target $181 implies near-zero upside from current levels | A major sell-side firm explicitly values MMC below the current price. This is not just "one bearish analyst" -- it reflects a coherent view that growth deceleration + leverage justifies a lower multiple. | MODERATE |

### Riesgos

| # | Desafio | Evidencia | Severidad |
|---|---------|-----------|-----------|
| 1 | Greensill Australia A$7B trial (Aug 2026) is a material binary risk not treated as hard gate | 5-month trial starts Aug 2026. Court has ruled against Marsh on procedural matters. If fraud is found, E&O insurance may not cover. Potential $500M-$1B+ net exposure. | HIGH |
| 2 | Four HIGH risks are CORRELATED -- AI + rate softening + leverage all hit revenue simultaneously | In a bear scenario, AI depresses mid-market (McGriff), rate softening compresses commissions, and $350M+ annual interest on McGriff debt is a fixed cost burden against declining revenue. | HIGH |
| 3 | Insider selling: CEO sold $3.8M at $182 -- exactly the current price | While potentially routine (10b5-1 plan), the CEO sold near the current price. Net insider selling of -$76M over 2 years for a $90B company is small but directionally negative. 0.1% insider ownership means management has minimal "skin in the game." | LOW |
| 4 | P&C rate softening cycle may be deeper and longer than thesis assumes | Property rates down 10-30% in 2025. Cat reinsurance down 14.7% at Jan 2026 renewals. KBW expects approaching -20%. This directly compresses broker commissions (% of premium = lower premium = lower commission). | MODERATE |
| 5 | Historical precedent: Spitzer investigation 2004 cost MMC $850M and destroyed the stock | MMC has a HISTORY of regulatory/legal tail risk events. The Greensill situation (alleged misrepresentation of insurance coverage) rhymes with the Spitzer bid-rigging scandal. The 2004-2005 crisis led to CEO dismissal, $850M settlement, and fundamental business model changes. | MODERATE |

### Timing

| # | Desafio | Evidencia | Severidad |
|---|---------|-----------|-----------|
| 1 | Stock is at 52-week low ($170.78 intraday Feb 13) -- but "catching a falling knife" risk | The stock has fallen 31% from its high. The decline accelerated in Feb 2026 with the Insurify selloff. There is no clear technical support level or fundamental catalyst for a reversal in the near term. | MODERATE |
| 2 | Greensill trial Aug 2026 creates a 6-month binary overhang | Any position taken now faces 6 months of Greensill uncertainty. If the trial goes badly, the stock could gap down 10-15% on adverse headlines even before a final verdict. | MODERATE |
| 3 | Rate softening cycle typically lasts 2-3 years -- we are in year 1 | If the soft market began in mid-2025, organic growth may not recover until 2027-2028. This is a long period of muted revenue growth for a stock trading at 22x earnings. | MODERATE |
| 4 | No near-term catalyst identified by BofA | BofA specifically cited "no near-term catalysts supporting organic growth." The thesis lists catalysts (McGriff synergies, hard market return, margin expansion) but all are 6-18 months out. Dead money risk is real. | MODERATE |

---

## Conflictos con Otros Analisis

### Thesis vs Valuation Report: FV CONFLICT

The thesis body states FV $220 and derives entry from that ($160 = 27% MoS vs $220). The valuation-specialist report independently arrives at FV $190 with 17% method divergence (within acceptable range). The valuation-specialist explicitly recommends adopting $190 as the canonical FV. The thesis header has been updated to $190 but the body text, scenarios section, and MoS calculations still reference $220. This MUST be resolved -- the investment committee should evaluate against $190, not $220.

At $190 FV, the entry of $160 provides only 16% MoS (vs Expected Value $191). This is below the 20-25% typical Tier B MoS from decisions_log.yaml. The valuation-specialist acknowledged this gap and argued the WIDE moat and recurring revenue justify slightly lower MoS. However, given 4 HIGH risks identified by the risk-identifier and the Greensill binary tail risk, accepting 16% MoS for Tier B is a deviation from precedent that must be explicitly reasoned.

### Moat Assessment vs Risk Assessment: Tension on AI

The moat-assessor rates AI disruption as "Low-Medium" probability, "Low" impact for MMC, calling the Feb 9 selloff an "overreaction driven by narrative contagion." The risk-identifier rates the same AI risk as "Medium" probability, "High" impact and identifies it as the #1 risk, calling it "the #1 reason the stock is at 52w low." These assessments are in DIRECT CONFLICT on the impact dimension.

My independent assessment: the risk-identifier is closer to correct. The moat-assessor correctly notes that complex commercial broking is safe from ChatGPT comparison apps. But the moat-assessor underweights: (a) McGriff's mid-market exposure ($2.5B revenue) which is MORE vulnerable, and (b) the consulting segment (35% revenue) which faces direct AI substitution risk. The moat is WIDE for Marsh's core large commercial broking -- but the WIDE moat protects only ~55% of revenue, not 100%.

### Risk Assessment: Greensill not recommended as hard gate

The risk-identifier correctly identifies Greensill as HIGH risk (#2 of top 3) but explicitly says "Kill condition? NO." The risk-identifier recommends monitoring the August 2026 trial but does NOT recommend it as a hard gate that should preclude position entry. Given the potential $500M-$1B+ exposure (10-20% of annual net income), the historical Spitzer precedent ($850M in 2005), and the court's unfavorable procedural rulings, this risk is being UNDERWEIGHTED. Any adverse headline from the trial could send the stock down 5-10% from wherever it trades.

---

## Veredicto Global

| Metric | Valor |
|--------|-------|
| Desafios totales | 19 |
| Desafios HIGH | 3 |
| Desafios MODERATE | 13 |
| Desafios LOW | 3 |
| Desafios no resueltos por thesis | 5 (Greensill as hard gate, FV conflict, MoS below precedent, consulting AI risk, McGriff mid-market AI vulnerability) |
| **Veredicto** | **MODERATE COUNTER** |

### Interpretacion

**MODERATE COUNTER:** The thesis identifies a genuinely excellent business with a WIDE moat. The core analysis of MMC's competitive position, business model, and moat durability is sound and well-researched. However, the thesis has gaps that require resolution before the investment committee can approve:

1. The FV must be settled at $190 (valuation-specialist), not $220 (thesis body text).
2. The Greensill trial (Aug 2026) should be a hard gate or at minimum a position-sizing constraint.
3. The entry of $160 provides only 16% MoS vs $190 FV, which is below Tier B precedents. Either the entry should be lowered to $150-155, or the WIDE moat + recurring revenue must be explicitly argued as justifying reduced MoS.
4. The consulting segment's AI vulnerability (35% of revenue) needs a kill condition or monitoring framework.
5. The 4% organic growth should be treated as baseline for 2026-2027, not a temporary trough.

**Conviction Score: 13/20**

The business quality is high (8/10) but the valuation (3/5) and risk management (2/5) need work. The thesis is NOT wrong about MMC being a great business. The question is whether $160 is the right price given the specific risks identified, or whether patience for $150 or lower (or resolution of Greensill) is the prudent path.

---

## Recommended Adjustments

| Parameter | Thesis Value | Recommended | Reasoning |
|-----------|-------------|-------------|-----------|
| **Fair Value** | $220 (thesis) / $190 (valuation report) | **$190** | Adopt valuation-specialist's rigorous 3-method weighted average. $220 is bull-case achievable, not base. |
| **QS Adjusted** | 68 | **68** (no change) | The +4 adjustment for market position is justified with evidence. QS tool underscores MMC due to ROIC calculation on leveraged balance sheet. |
| **Entry** | $160 | **$155** | $155 provides 18.4% MoS vs $190 EV, closer to Tier B precedents (ROP 22%, ACGL 23%). Alternatively, maintain $160 but treat Greensill as hard gate. |
| **Kill Conditions** | 5 listed | **Add 2 more:** (1) Greensill adverse judgment >$1B net to Marsh, (2) AI-native broker captures >2% US mid-market commercial within 18 months | Greensill must be explicit. McGriff mid-market AI risk needs monitoring. |
| **Hard Gates** | None | **Add: Greensill trial (Aug 2026)** | Do not deploy full position before Greensill resolution or at minimum size position to survive $1B adverse outcome. |
| **Bear Case FV** | $155 (thesis) / $148 (valuation) | **$145** | Incorporate Greensill $500M settlement + organic growth stuck at 3% scenario. |

---

## Recomendacion al Investment Committee

1. **RESOLVE the FV conflict.** The canonical FV must be $190 (valuation-specialist), not $220. All MoS calculations and forward_return.py references should use $190.

2. **DECIDE on Greensill hard gate.** The committee should determine whether the August 2026 trial is (a) a hard gate that prevents position entry, (b) a sizing constraint that limits position to 2-3% until resolved, or (c) acceptable risk at full sizing. My recommendation is option (b) -- take a smaller position if price reaches $155-160, with ADD conditional on Greensill settlement or favorable trial progress.

3. **LOWER entry to $155 or explicitly argue for reduced MoS.** At $160, MoS is 16% vs $190 EV. This is 4-9 percentage points below recent Tier B precedents (ROP 22%, ACGL 23%, RACE.MI 26%). The WIDE moat argument is real but must be explicitly documented as the justification for accepting lower MoS. The valuation-specialist partially made this argument but the committee should formalize it.

4. **ADD consulting AI risk monitoring.** The thesis identifies AI as "enabler for brokers" but does not address the consulting segment (35% revenue). Add monitoring: Mercer and Oliver Wyman organic growth rates should be tracked quarterly. If combined consulting organic growth falls below 2% for 2 consecutive quarters, the thesis needs reassessment.

5. **MONITOR organic growth trajectory.** If FY2026 organic growth comes in below 3% (vs guided "similar to 2025" i.e. ~4%), this signals structural deceleration beyond cyclical softening and the thesis should be downgraded.

---

## META-REFLECTION

### Dudas/Incertidumbres
- **Greensill quantum:** I could not find Marsh's specific liability share within the A$7B total. The exposure could range from A$200M to A$3B+ depending on the court's allocation. This is a genuinely unknowable risk until the trial produces evidence.
- **AI disruption speed for mid-market:** I believe the thesis underweights McGriff's mid-market AI vulnerability, but I cannot quantify the timeline with confidence. The Insurify app currently handles only personal auto -- extension to mid-market commercial is plausible but unproven.
- **Multiple de-rating permanence:** Is the compression from 28-30x to 22x P/E temporary (cyclical fear) or permanent (structural re-pricing for AI risk)? If permanent, FV drops significantly. I lean toward "mostly temporary with some permanent component" but cannot prove this.

### Limitaciones de Este Analisis
- I could not access MMC's actual 10-K/10-Q for Greensill litigation disclosure details (reserve amounts, specific claims). The risk-identifier used news sources which may not capture the full legal picture.
- Insider selling data was limited to public filings found via web search. A comprehensive insider transaction analysis (OpenInsider or similar) would provide better signal.
- I did not have access to sell-side research reports from BofA, Goldman, or Wells Fargo -- only their price targets and ratings via news articles.

### Sugerencias para el Sistema
- The insurance sector view should track insurance broker-specific metrics (organic growth by segment, rate cycle phase, fiduciary interest income) separately from underwriter metrics. This would make the sector view more useful for broker analysis.
- For companies with major pending litigation (Greensill), the risk assessment should include a "litigation probability tree" with explicit probability-weighted outcomes rather than a qualitative "Media probability, Alto impact."
- The quality_scorer.py underscores insurance brokers because ROIC (14%) looks modest for what is really a 27% ROE business. The suggestion from the thesis META-REFLECTION to add a "financial leverage amplifier" flag is valid and would affect MMC, AON, exchanges (ICE, CME), and asset managers.

### Preguntas para Orchestrator
1. What is the Greensill hard gate policy? Should all companies with pending mega-litigation (>$500M potential exposure) have a hard gate or sizing constraint?
2. The entry at $160 provides 16% MoS -- do we accept this as adequate for WIDE moat Tier B, or do we require 20%+ consistent with precedents? This sets a precedent for future WIDE-moat Tier B entries.
3. Should the McGriff mid-market AI exposure be added to the broader "SaaSpocalypse" tracking that currently monitors software positions? Mid-market insurance broking and SaaS per-seat pricing are different risks but both stem from AI disrupting intermediary/seat-based revenue models.
4. The moat-assessor and risk-identifier gave conflicting AI impact assessments (Low vs High). How should the committee weigh this when both reports are produced by opus-level agents?

---

## Sources

### Analyst Ratings & Downgrades
- [BofA Downgrades MMC to Underperform, $181 PT](https://www.investing.com/news/analyst-ratings/marsh--mclennan-stock-downgraded-to-underperform-by-bofa-on-growth-concerns-93CH-4326893)
- [Goldman Sachs Upgrades to Neutral, $195-203 PT](https://www.marketscreener.com/news/goldman-sachs-upgrades-marsh-mclennan-to-neutral-from-sell-adjusts-price-target-to-195-from-200-ce7d5ad2dd8efe24)
- [Wells Fargo Lowers PT to $199](https://finance.yahoo.com/news/marsh-mclennan-companies-mmc-story-181453554.html)
- [Cantor Fitzgerald Lowers PT to $208](https://www.gurufocus.com/news/4110868/analyst-cantor-fitzgerald-lowers-price-target-on-marsh-mclennan-mmc-mmc-stock-news)

### Greensill Litigation
- [Marsh Loses Anti-Anti-Suit Over Greensill $7B Lawsuit](https://www.insurancebusinessmag.com/au/news/breaking-news/marsh-loses-important-antiantisuit-over-greensill-7-billion-lawsuit-552859.aspx)
- [Marsh Settles UK White Oak Claim ($143M)](https://www.insurancebusinessmag.com/us/news/legal-insights/marsh-mclennan-settles-giant-lawsuit-536578.aspx)

### AI Disruption
- [Insurance Broker Stocks Sink as AI App Sparks Disruption Fears](https://www.insurancejournal.com/news/national/2026/02/10/857525.htm)
- [AI vs Brokers: First ChatGPT Broker App Stokes Fears](https://www.insurancebusinessmag.com/us/news/technology/ai-vs-brokers-first-chatgpt-broker-app-stokes-disintermediation-fears-565003.aspx)
- [Insurance Brokers Crash: WTW Worst Day Since 2008](https://fintool.com/news/insurance-brokers-ai-disruption-chatgpt-selloff)

### Organic Growth & Rate Softening
- [Marsh Reports 4% Organic Growth for Q4/FY2025](https://www.insurancejournal.com/news/national/2026/01/29/856155.htm)
- [P&C Market Enters Correction Phase](https://riskandinsurance.com/pc-market-enters-correction-phase-with-significant-rate-relief-and-emerging-challenges/)
- [Property Cat Reinsurance Down 14.7% at Jan 2026 Renewals](https://www.artemis.bm/news/property-cat-reinsurance-down-14-7-retrocession-down-16-5-at-jan-2026-renewals-howden-re/)

### Insider Activity
- [CEO Sells 21,079 Shares at $182](https://www.marketbeat.com/instant-alerts/insider-selling-marsh-mclennan-companies-nysemmc-ceo-sells-21079-shares-of-stock-2025-12-03/)

### McGriff Integration
- [Marsh McLennan Q4 2025 Earnings Transcript](https://www.investing.com/news/transcripts/earnings-call-transcript-marshs-q4-2025-revenue-climbs-amid-strategic-investments-93CH-4473733)
- [Evercore Highlights Acquisition Synergies](https://www.investing.com/news/analyst-ratings/marsh--mclennan-stock-gains-momentum-as-evercore-highlights-acquisition-synergies-93CH-3738876)

### Historical Precedent
- [Spitzer Charges Marsh & McLennan in Insurance Racket (2004)](https://www.thestreet.com/markets/spitzer-charges-marsh-mclennan-in-insurance-racket-10187969)
- [Marsh Settles for $850M (2005)](https://www.chicagotribune.com/2005/02/01/marsh-mclennan-to-pay-850-million-in-settlement/)
